Immune Thrombocytopenia
We recommend
How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
Central European Expert Consensus on the Treatment of ITP in Adult Patients
In a recently published consensus, experts from Central Europe evaluate the current treatment…
ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…
Articles on this topic
Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?
Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only…
How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?
What is the perception and view of the treatment options for immune thrombocytopenia (ITP)…
Romiplostim brings benefit also to patients with ITP lasting less than 1 year
What is the role of second-line therapy, in this case romiplostim, in the management of adult…
Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment – Case Study
In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding…
Romiplostim in ITP Treatment – Data from German Clinical Practice
Real-world clinical practice data from Germany confirm the beneficial effect and safety…
Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as…
Overuse of Corticosteroids as a Serious Problem in ITP
Corticosteroids (CS) are a common part of the treatment for immune thrombocytopenia (ITP).…
Romiplostim in Newly Diagnosed or Persistent ITP
Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly…
Initial Treatment for Newly Diagnosed ITP Patients at a Glance
The revised international consensus on the management of primary immune thrombocytopenia (ITP)…
ITP from the Patients' Perspective: How It Affects Their Lives and Which Needs They Find Unmet?
In recent years, new therapeutic options for immune thrombocytopenia (ITP) have been…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- COVID-19 and Immune Thrombocytopenic Purpura − Spanish Experience Suggests Surprising Connections
- Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection
- Thrombocytopenia Following mRNA Vaccination Against SARS-CoV-2
- Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective
- Summary of Recommendations for the Treatment of Immune Thrombocytopenia in Pregnancy
- Current ASH Guidelines on ITP Management 2019 – Recommendations for Newly Diagnosed ITP in Children
Journal on this topic
Related topic